Korean J Pancreas Biliary Tract.  2020 Jul;25(2):65-71. 10.15279/kpba.2020.25.2.65.

The Screening and Early Detection of Pancreatic Cancer: Who, When, and How?

• Chang JH

• KMID: 2504996
• DOI: http://doi.org/10.15279/kpba.2020.25.2.65

Abstract

More than 80% of patients with pancreatic ductal adenocarcinoma (PDA) present with symptomatic, surgically unresectable disease. If a “stage shift” from the current 20% resectable proportion to greater by early detection can be achieved, it will unequivocally lead to improved survival in this otherwise dismal disease. Although the goal of early detection of PDA is laudable, the relatively low prevalence PDA renders general population screening infeasible. To avoid the perils of overdiagnosis and to focus early detection efforts on individuals deemed to be at higher-than-average risk, we need to define those subsets of individuals, such as familial kindred and patients with precursor cystic lesions, chronic pancreatitis, and new-onset diabetes. The next step is to determine when and how often to conduct surveillance in the atrisk individuals and the modalities (biomarkers and imaging) that will be used in the surveillance and diagnostic settings, respectively. Nonetheless, vast challenges still remain in terms of validated blood-based biomarkers, imaging modality, and when and how often the surveillance.

Keyword

췌장암; 조기 발견; 선별 검사; Pancreatic neoplasm; Early detection of cancer; Population surveillance; Biomarkers